Ultrasonic characterization of canine myocardium contraction.

Department of Medicine, Stanford University, Palo Alto, California, United States
IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control (Impact Factor: 1.5). 02/1986; 33(4):347-53. DOI: 10.1109/T-UFFC.1986.26841
Source: PubMed

ABSTRACT Absfracf-Other investigators have found ultrasonic backscatter from canine myocardium to exhibit a significant variation throughout the cardiac cycle. Also, several studies have shown a change in an ultrasonic property of canine myocardium when ischemia is induced. In an attempt to gain some understanding of the physical mechanisms responsible for these variations, several ultrasonic measurements were made on canine papillary muscle in vitro during both isotonic (constant load) and isometric (constant length) contractions. Integrated backscatter was found to exhibit a significant cyclic variation (p < 0.05) during isotonic (constant load) contractions, but not during isometric (constant length) contractions. This result suggests that the variation in the physical arrangement of structures within the tissue that occurs during contraction plays an important role in determining ultrasonic backscatter. No significant cyclic variation was found in the backscattered signal envelope statistics or in acoustic attenuation during either isotonic or isometric contractions.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Hopefully this chapter has provided the reader with insights regarding how measurements of fundamental ultrasonic parameters are related to the presence of myocardial fibrosis and how these measurements lay the foundation for the continuing development of clinically applicable noninvasive ultrasonic assessment techniques. Several studies were cited which show how ultrasonic propagation and scattering are directly related to fundamental physical properties of myocardium and hence ultrasonic tissue characterization techniques are well-suited for the direct measurement of specific myocardial properties. The clinical utility of ultrasound-based noninvasive assessment techniques, such as measurements of the cyclic variation of backscattered energy over the heart cycle, have been clearly demonstrated. Nonetheless significant challenges remain before these techniques can be routinely applied in clinical practice. Enhanced measurement techniques which increase the reliability and decrease the uncertainty associated with clinical estimates of ultrasonic parameters will help foster the continued acceptance of these methods. Development of additional robust reference measurement methods that permit compensation of the measured ultrasonic backscatter for the effects of the imaging system will provide absolute measures of inherent ultrasonic properties of myocardium. A better understanding of the underlying mechanisms associated with the observed ultrasonic properties (e.g., the role of scatterer (myocyte) size, number density, myocardial fiber orientation, inherent viscoelastic properties of the intra- and extracellular components) will enhance the interpretation of ultrasonic measurements and permit direct assessment of specific myocardial properties. The future for ultrasonic-based methods of directly characterizing myocardium continues to look promising and these techniques will continue to be useful tools for the assessment of properties such as the degree and nature of myocardial fibrosis.
    12/2004: pages 115-148;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tissue characterization previously identified ischemia, infarction, and cardiomyopathy in animal myocardium. Investigations to determine whether analogous results occur in patients were undertaken with a real-time two-dimensional backscatter imaging system. Remote infarction in 15 patients was accompanied by reduced magnitude and delayed cyclic variation. Similarly, ultrasonic evidence of diminished contractile function was found in five patients with dilated cardiomyopathy compared to 15 patients in a control group. Studies of 15 patients with acute myocardial infarction indicate that tissue characterization may permit the detection of reversibly injured or `stunned' myocardium, despite the presence of severe wall-motion abnormalities that might otherwise mask the presence of viable but transiently dysfunctional tissue
    Ultrasonics Symposium, 1989. Proceedings., IEEE 1989; 11/1989
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ultrasonic tissue characterization by integrated backscatter is a sensitive tool to detect myocardial changes related to specific diseases. Cardiotoxicity related to doxorubicin use is well known and remains a major concern. To determine if ultrasonic tissue characterization of the myocardium is abnormal in patients receiving doxorubicin, we studied the myocardium of pediatric patients receiving doxorubicin by a real-time integrated backscatter (IB) imaging system. Three values of IB parameters were averaged from the left ventricular posterior wall at the level of the tip of the mitral valve. In addition to standard echo parameters, we obtained the following IB parameters: peak, nadir, cyclic variation (CV), end-diastole, heart-rate corrected delay of nadir (Delayc), and the ratio of CV over end-diastole. IB parameters were normalized as Z scores from multiple linear regression equations including echo wall thickness and functional indices from a normal control group of 72 children. We evaluated 27 patients at a median age of 11.6 years (1.6 years to 20.3 years) and median time of 1.7 m (2 days to 7.2 years) after a mean cumulative dose of doxorubicin of 188 ± 120 mg/m2 for treatment of neoplasm. Mean (± SD) Z scores for IB variables were as follows: zPeak 0.15 ± 1.07, P = 0.47; zNadir 0.41 ± 1.16, P = 0.08; zCV -0.49 ± 0.95, P = 0.01; zEnd-diastole 0.17 ± 0.94, P = 0.38; zDelayc 0.33 ± 0.80, P = 0.06, and zCV/Peak -0.59 ± 1.06, P = 0.009. This study shows that ultrasonic IB of the myocardium of children receiving doxorubicin is abnormal and is independent of the cumulative dosage of doxorubicin or the amount of time since the last dose.
    Echocardiography 01/1998; 15(2):121 - 125. DOI:10.1111/j.1540-8175.1998.tb00587.x · 1.25 Impact Factor